U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (EMR/EHR/Clinical Data, Claims & Billing Data, Pharmacy Data, Product/Disease Registries Data, Integrated Datasets)], Application (Market Access & Reimbursement, Drug Development & Approvals), End User ΓÇô Forecast to 2036

The U.S. real-world evidence (RWE) solutions market was valued at USD 1.31 billion in 2025. This market is expected to reach USD 3.52 billion by 2036 from USD 1.46 billion in 2026, at a CAGR of 9.2% from 2026 to 2036.

Real-world evidence (RWE) is clinical evidence regarding the use and potential benefits or risks of a medical product derived from the analysis of real-world data (RWD). RWD refers to data relating to patient health status and the delivery of healthcare routinely collected from a variety of sources including electronic health records (EHRs), medical claims and billing data, product and disease registries, patient-generated data from digital health technologies, and data gathered through patient surveys. RWE can be produced through various study designs or analyses, including but not limited to observational studies (prospective and retrospective), randomized pragmatic trials, and externally controlled trials. RWE has applications across the pharmaceutical and medical device product life cycle, including drug and device development, regulatory submissions, label expansions, market access and coverage decisions, post-market safety surveillance, and health technology assessment.

The growth of the U.S. RWE solutions market is driven by rapidly growing big data in healthcare, the shift from volume-based to value-based care, the rising focus toward personalized healthcare and precision medicine, and increasing regulatory acceptance of RWE by the U.S. Food and Drug Administration (FDA). Furthermore, the rising adoption of artificial intelligence and machine learning in RWD analysis and the growing integration of genomic data into RWE datasets are expected to offer significant growth opportunities. However, data quality and interoperability challenges across disparate real-world data sources and concerns about data privacy and security remain restraints on market growth.

• In terms of revenue, the U.S. RWE solutions market is valued at USD 1.46 billion in 2026 and is projected to reach USD 3.52 billion by 2036.
• The market is expected to grow at a CAGR of 9.2% from 2026 to 2036.
• By component, the datasets segment holds the largest share of the overall U.S. RWE solutions market in 2026.
• By component, the consulting and analytics segment is expected to witness the fastest CAGR during the forecast period.
• By application, the market access & reimbursement/coverage decisions segment holds the largest share of the overall U.S. RWE solutions market in 2026.
• By application, the drug development & approvals segment is expected to witness the fastest CAGR during the forecast period.
• By end user, the pharmaceutical, biotechnology & medical device companies segment holds the largest share of the overall U.S. RWE solutions market in 2026.

Click here to: Get Free Sample Pages of this Report

Real-world evidence solutions include the data assets, software platforms, analytical services, and consulting capabilities that enable life sciences companies, healthcare payers, healthcare providers, regulatory agencies, and other stakeholders to generate, analyze, and apply RWE derived from real-world healthcare data. The U.S. is the largest market for RWE solutions globally, driven by the extensive availability of structured real-world healthcare datasets including medical claims data from commercial insurers, Medicare and Medicaid; EHR data from large integrated health systems and ambulatory networks; specialty pharmacy and specialty distribution data; hospital charge data and chargemaster records; and a growing ecosystem of patient-generated data from wearables, digital health platforms, and decentralized clinical trials.

The FDA has significantly expanded its regulatory framework for RWE since the enactment of the 21st Century Cures Act in December 2016, which required the FDA to issue guidance on the use of RWE in regulatory decision-making. The FDA published final guidance on "Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products" in August 2023, establishing a framework for evaluating RWE to support new indication approvals or postapproval study requirements for drugs and biologics. In July 2024, the FDA finalized the guidance "Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products," providing updated recommendations on assessing the relevance and reliability of EHR and claims data for regulatory submissions, while acknowledging emerging technologies such as AI for processing unstructured data. In December 2025, the FDA finalized its updated guidance on the use of RWE to support regulatory decision-making for medical devices, superseding the prior 2017 guidance and providing expanded recommendations aligned with the Food and Drug Omnibus Reform Act of 2022 (FDORA), including detailed considerations for when IDE requirements apply to RWD-based studies.

The FDA’s Advancing RWE Program, a commitment under PDUFA VII enacted as part of the FDA User Fee Reauthorization Act of 2022, provides sponsors with the opportunity to engage with FDA staff during the study planning and design phase to discuss the use of RWE in drug development, including for labeling-supportive evidence generation and post-approval study requirements. The FDA’s Center for Drug Evaluation and Research (CDER) is also tracking regulatory submissions incorporating RWE under PDUFA VII, including new study protocols, final study reports, and NDA and BLA applications containing RWE components from fiscal year 2023 through 2027. These regulatory developments are contributing to increased clarity and confidence among pharmaceutical, biotechnology, and medical device companies seeking to incorporate RWE into regulatory submissions, thereby driving demand for high-quality integrated RWD datasets and advanced RWE analytics services.

Growing Integration of Artificial Intelligence and Machine Learning in RWD Analysis

One of the significant trends in the U.S. RWE solutions market is the growing integration of artificial intelligence (AI) and machine learning (ML) in the curation, processing, and analysis of real-world data. AI and ML technologies are enabling RWE solutions providers to extract structured information from unstructured clinical text in EHR systems, improve the accuracy and completeness of patient-level data through natural language processing, automate variable identification and validation in large-scale observational studies, and accelerate the turnaround time of RWE studies for regulatory, market access, and clinical decision-making purposes. In January 2025, IQVIA Holdings Inc. and NVIDIA Corporation announced a collaboration to accelerate the use of artificial intelligence in healthcare and life sciences through the development of AI-enabled solutions leveraging IQVIA’s extensive proprietary healthcare datasets to automate complex tasks such as literature synthesis, clinical data review, and clinical trial site identification. In March 2025, ICON plc launched PatientSourceDuo, a linked real-world data asset integrating healthcare claims datasets to support longitudinal analysis across the patient journey for clinical research and commercial evidence generation strategies.

The integration of generative AI and large language models into RWE platforms is enabling new analytical capabilities such as automated cohort identification, protocol drafting, and regulatory-grade study report generation. The growing availability of AI-assisted RWD curation tools is reducing the labor intensity of preparing large-scale RWD sources for analytical use, broadening the range of RWD that can be productively incorporated into RWE studies. This trend is creating demand for AI-enabled RWE software platforms and analytics services that can support both exploratory and confirmatory RWE generation at scale.

Expanding Regulatory Acceptance of RWE and Growth of the FDA Advancing RWE Program

The expanding regulatory acceptance of RWE for drug and device labeling, post-approval commitments, and supplemental approval decisions is a significant trend driving demand for high-quality RWE solutions in the U.S. market. The FDA’s publication of final and draft guidances on the use of RWD and RWE in regulatory decision-making since 2023, combined with active engagement under the FDA’s Advancing RWE Program established through PDUFA VII, has increased confidence among pharmaceutical, biotechnology, and medical device companies in the regulatory use of RWE. FDA leadership has also emphasized the growing role of electronic health record-derived real-world data in supporting regulatory-grade evidence generation. These developments are driving increased investment by life sciences companies in building or procuring the RWD infrastructure and RWE analytical capabilities needed to generate regulatory-grade RWE.

The growing use of RWE in health technology assessment and payer coverage decisions is also supporting market growth. The U.S. commercial insurers, pharmacy benefit managers, and government payers, including the Centers for Medicare & Medicaid Services, are increasingly incorporating RWE into formulary management, coverage with evidence development programs, and outcomes-based contracting arrangements. The Inflation Reduction Act of 2022, which established a Medicare drug price negotiation program, has further increased the importance of RWE in demonstrating the value of high-cost medicines in real-world clinical settings relative to therapeutic alternatives, creating growing demand for RWE solutions that support market access and health economic analysis.

Growing Incidence of Chronic and Infectious Diseases and Rising Focus on Personalized Healthcare

The growing incidence of chronic diseases such as cardiovascular diseases, oncological conditions, diabetes, neurological disorders, and respiratory diseases is increasing the volume of real-world health data generated by healthcare systems and the demand for RWE to understand real-world treatment patterns, safety signals, and outcomes in these patient populations. Chronic diseases account for the majority of healthcare expenditure in the U.S., and payers, pharmaceutical companies, and health systems are increasingly investing in RWE capabilities to understand the real-world effectiveness and cost-effectiveness of treatments for these conditions.

The rising focus on precision medicine and personalized healthcare is also driving demand for RWE solutions that can integrate clinical, genomic, biomarker, and patient-reported data to support the development and evaluation of targeted therapies. The growing availability of integrated datasets linking clinical EHR data with molecular profiling data, imaging data, and patient-reported outcomes data is creating new opportunities for RWE generation in precision oncology, rare diseases, and other therapeutic areas where large-scale randomized trials are not feasible.

Shift from Volume to Value-Based Care and Rapidly Growing Big Data in Healthcare

The ongoing shift of the U.S. healthcare system from volume-based to value-based care reimbursement models is another key driver of the RWE solutions market. Value-based care arrangements including accountable care organizations, bundled payment programs, and outcomes-based pharmaceutical contracting require demonstrated evidence of real-world health outcomes, resource utilization, and total cost of care. These requirements are creating growing demand from healthcare providers, payers, and pharmaceutical and medical device companies for RWE solutions that can generate and analyze patient-level evidence from real-world healthcare data.

The rapidly growing volume of digital health data generated in the U.S. healthcare system, including EHR data, medical claims data, specialty pharmacy data, patient-generated data from wearable devices and digital health applications, and data from decentralized clinical trials, is expanding the foundation of RWD available for RWE generation. The increasing digitization of healthcare data and the growing interoperability of EHR systems under the mandates of the 21st Century Cures Act and the CMS Interoperability and Patient Access Rule are improving the availability and quality of real-world healthcare data accessible for RWE studies.

Why Does the Datasets Segment Dominate the U.S. RWE Solutions Market?

Based on component, in 2026, the datasets segment is expected to account for the largest share of the U.S. RWE solutions market. The large share of this segment is primarily attributed to the increasing need for additional insights on epidemiology, patient compliance, treatment adherence, and healthcare costs in realistic clinical settings; the growing volume of medical data generated in U.S. hospitals and health systems; the increasing dependence of outcome-based studies on real-world data; and the rising demand for information regarding drug safety among payers, regulatory bodies, and healthcare providers. The datasets segment includes disparate datasets encompassing EMR/EHR data, medical claims and billing data, pharmacy data, and product and disease registry data, as well as integrated datasets linking multiple data sources at the patient level.

However, the consulting and analytics segment is expected to grow at the fastest CAGR during the forecast period. The growth of this segment is driven by the increasing complexity of RWE study design and the growing demand for end-to-end RWE services that combine dataset access with study design expertise, statistical analysis, regulatory strategy, and results communication. Pharmaceutical, biotechnology, and medical device companies are increasingly seeking full-service RWE partners that can support the complete evidence generation process, from protocol development and data curation through analysis, regulatory submission preparation, and publication, rather than solely providing access to raw RWD.

Why Does the Market Access & Reimbursement Segment Dominate the U.S. RWE Solutions Market?

Based on application, in 2026, the market access and reimbursement/coverage decisions segment is expected to account for the largest share of the U.S. RWE solutions market. The large share of this segment is primarily attributed to the increasing demand for real-world data and real-world evidence to support payer negotiations, formulary positioning, coverage decisions, and outcomes-based contracting for pharmaceutical and medical device products. The U.S. payers, including commercial insurers, pharmacy benefit managers, and government programs, use RWD to support coverage decisions, develop clinical guidelines and decision support tools, generate estimates of the population requiring treatment, and model potential costs and cost offsets. The Inflation Reduction Act of 2022’s Medicare drug price negotiation program has further elevated the role of RWE in demonstrating the value of medicines in real-world settings.

However, the drug development and approvals segment is expected to grow at the fastest CAGR during the forecast period. The growth of this segment is mainly driven by increasing investment by biopharmaceutical companies in using RWE to support regulatory submissions, including label expansions, supplemental approvals, and post-approval study commitments; the growing regulatory acceptance of RWE by the FDA under the PDUFA VII Advancing RWE Program and related guidances; and increasing demand for RWE to support the development of targeted therapies in oncology, rare diseases, immunology, and neurology where RCT-based evidence generation is challenging.

Why Do Pharmaceutical, Biotechnology & Medical Device Companies Dominate the U.S. RWE Solutions Market?

Based on end user, in 2026, the pharmaceutical, biotechnology, and medical device companies segment is expected to account for the largest share of the U.S. RWE solutions market. The large share of this segment is mainly attributed to the increasing importance of RWE studies in drug development and regulatory approvals, the growing need to avoid costly drug recalls and assess drug performance in real-world settings, and the increasing use of RWE to support label expansion and supplemental approval applications. Pharmaceutical companies are increasingly utilizing real-world evidence for collecting real-time post-trial information about drugs, which helps healthcare providers and researchers understand adverse reactions, side effects, and medication errors, enabling better pharmacovigilance and risk management. The growing requirement for post-marketing commitments and post-approval study requirements in FDA approvals is also driving demand for RWE services among pharmaceutical and medical device companies.

The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by major market participants in the U.S. RWE solutions market between 2022 and 2025. The key players profiled in the U.S. RWE solutions market report are IQVIA Holdings Inc. (U.S.), Optum, Inc. (UnitedHealth Group) (U.S.), Elevance Health, Inc. (U.S.), ICON plc (Ireland), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), SAS Institute Inc. (U.S.), Thermo Fisher Scientific Inc. (PPD Inc.) (U.S.), Flatiron Health, Inc. (U.S.), Aetion, Inc. (U.S.), TriNetX, LLC (U.S.), Merative (U.S.), Medidata Solutions (a Dassault Systèmes company) (U.S.), and Fortrea Holdings Inc. (U.S.), among others.

U.S. RWE Solutions Market, by Component

• Datasets
•   Disparate Datasets
•     EMR/EHR/Clinical Data
•     Claims & Billing Data
•     Pharmacy Data
•     Product/Disease Registries Data
•     Other Disparate Datasets
•   Integrated Datasets
• Consulting and Analytics

U.S. RWE Solutions Market, by Application

• Market Access & Reimbursement/Coverage Decisions
• Drug Development & Approvals
•   Oncology
•   Neurology
•   Immunology
•   Cardiovascular Diseases
•   Other Therapeutic Areas
• Post-Market Surveillance
• Medical Device Development & Approvals
• Clinical and Regulatory Decision-Making

U.S. RWE Solutions Market, by End User

• Pharmaceutical, Biotechnology & Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Other End Users